Watson announced that it has received final FDA approval on its Abbreviated New Drug Application (ANDA) for Lidocaine Topical Patch 5%, the generic version of Endo Pharmaceutical‘s Lidoderm.

Lidocaine Topical Patch 5% is a topical anesthetic indicated for local pain and postherpetic neuralgia. Lidocaine reversibly blocks nerve conduction by reducing membrane permeability to sodium, producing a local analgesic effect.

Watson plans to launch the Lidocaine Topical Patch 5% in September 2013 pursuant with its settlement agreement with Endo and that under Hatch Waxman rules, it will be entitled to 180 days of marketing exclusivity. The agreement allows Watson to launch its product on September 15, 2013.

For more information call (800) 272-5525 or visit www.watson.com.